Liquid Cytisine Composition With pH Control for Stable Oral Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing nicotine addiction treatments, such as cytisine tablets and capsules, face challenges with compliance due to swallowing difficulties and require frequent dosing, and liquid formulations are lacking, with potential side effects like dry mouth.

Innovation Solution

A stable liquid pharmaceutical composition of cytisine is developed, using inorganic pH-regulating agents to maintain a pH between 3.0 and 7.5, free of organic salts or acids, and optionally including viscosity agents and co-solvents for easy administration as a mist, spray, or aerosol.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If cytisine is administered as tablets or capsules, then the medication can be delivered in a solid form, but patient compliance deteriorates due to swallowing difficulties and the need for frequent dosing

Engineering Contradiction:
Improvesolid pharmaceutical formVSAvoidpatient compliance
Core Design Contradiction:
Ease of manufactureVSEase of operation

Solution Approach 1:

The patent changes the physical state parameter of cytisine from solid (tablets/capsules) to liquid form, enabling administration without swallowing difficulties and allowing for more convenient dosing regimens while maintaining the active ingredient's efficacy

Inventive Principle:
Principle #35Parameter changes

2Stability of the object's composition

If tablets or capsules are used for cytisine administration, then the medication can be formulated in a stable solid form, but compliance worsens due to the requirement to take sufficient liquid with each dose

Engineering Contradiction:
Improvesolid formulation stabilityVSAvoidadministration convenience
Core Design Contradiction:
Stability of the object's compositionVSEase of operation

Solution Approach 1:

The patent transitions from solid tablet/capsule formulation to liquid formulation, eliminating the need to take additional liquid with each dose while maintaining composition stability through appropriate pH control and stabilizing agents

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs spray or aerosol delivery systems to administer the liquid cytisine composition, enabling easy application without requiring the patient to consume additional liquids, thus improving administration convenience

Inventive Principle:
Principle #29Pneumatics and hydraulics

3Ease of operation

If conventional liquid formulations are used, then administration convenience is improved, but chemical stability deteriorates due to pH fluctuations and degradation

Engineering Contradiction:
Improveliquid administration convenienceVSAvoidchemical stability
Core Design Contradiction:
Ease of operationVSStability of the object's composition

Solution Approach 1:

The patent optimizes the pH parameter of the liquid formulation to a specific range (pH 3-7, preferably pH 4-6) and employs pH-regulating agents to maintain stability, preventing cytisine degradation while preserving liquid form advantages

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent introduces stabilizing agents and pH-regulating components as intermediaries that protect cytisine from degradation in liquid form, enabling long-term chemical stability while maintaining the convenient liquid administration route

Inventive Principle:
Principle #24Intermediary (Mediator)

4Ease of operation

If cytisine tablets are administered, then the medication can be delivered in a convenient solid form, but side effects worsen due to dry mouth occurring in about 35% of patients

Engineering Contradiction:
Improvesolid dosage convenienceVSAvoiddry mouth side effect
Core Design Contradiction:
Ease of operationVSObject-generated harmful factors

Solution Approach 1:

The patent changes the dosage form from solid tablets to liquid spray/aerosol, allowing for localized oral cavity application that provides moisture and reduces dry mouth symptoms while delivering the required cytisine dose

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP4072517B1Liquid pharmaceutical composition comprising cytisine
Publication Date: 2026.04.01 ADAMED PHARMA SA

AI summary

The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH-regulating agent selected from the group consisting of inorganic acids, inorganic buffers, and inorganic acid salts, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention furthermore relates to the liquid pharmaceutical composition for use in the treatment of tobacco smoking addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco smoking addiction and other forms of nicotine addiction.